11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Weekly administration of solvent-based paclitaxel is one of the standard second-line chemotherapy regimens for advanced gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was developed to improve the solubility of paclitaxel and does not need premedication to avoid infusion-related reactions associated with solvent-based paclitaxel. Additionally, higher doses of nab-paclitaxel can be administered over a shorter infusion time and at higher drug concentrations compared with solvent-based paclitaxel. We aimed to investigate the efficacy and safety of nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer.

          Related collections

          Author and article information

          Journal
          The Lancet Gastroenterology & Hepatology
          The Lancet Gastroenterology & Hepatology
          Elsevier BV
          24681253
          April 2017
          April 2017
          : 2
          : 4
          : 277-287
          Article
          10.1016/S2468-1253(16)30219-9
          28404157
          554bb8d3-2084-402e-99c6-5d65cad25443
          © 2017

          http://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article